Status: Enrolling
Investigator: Eric Bernicker
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutation ... Read more >
Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
Major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR rate of pembrolizumab as a single agent. Additionally the dynami ... Read more >
Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator:
Phone:
This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in diffe ... Read more >
Status: Open Not Enrolling
Investigator: Jenny Chang
Study Coordinator:
Phone:
The purpose of this exploratory biomarker study is to further our understanding of the role of cancer stem cells (CSCs) and other biomarkers in the progression of COPD to lung cancer by examining the CSC population and other related biomarkers, ... Read more >
Status: Enrolling
Investigator: Jun Zhang
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3 ... Read more >
Status: Open Not Enrolling
Investigator: Jenny Chang
Study Coordinator: Syed Muhammad Saad
Phone: 281.276.5268
The purpose of this exploratory biomarker study is to further our understanding of the role of CSCs in lung cancer metastasis by examining the CSC population in metastatic tissue. ... Read more >
Status: Open Not Enrolling
Investigator: Jun Zhang
Study Coordinator:
Phone:
The study is an open-label, randomized, phase III trial to evaluate the addition of atezolizumab to standard chemoradiation for limited stage small cell lung cancer. Patients will be enrolled and randomized 1:1 between chemoradiation + atezolizu ... Read more >
Status: Enrolling
Investigator: Eric Bernicker
Study Coordinator:
Phone:
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand t ... Read more >
Status: Enrolling
Investigator: Eric Bernicker
Study Coordinator:
Phone:
This is a Phase I study evaluating the safety of atezolizumab in combination with ADV/IL-12 gene therapy in patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on first-line immunotherapy with or without chem ... Read more >
Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >
Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator: Lacey Burey
Phone: 713.441.1159
The purpose of this pilot study is to characterize the composition/diversity of the gut microbiome in patients with metastatic NSCLC who are receiving standard of care checkpoint blockade immunotherapy. This study will lay the groundwork for lar ... Read more >
Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator: Mary Rose Silvas
Phone: 713.441.1952
This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >
Status: Enrolling
Investigator: Nestor Esnaola
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
This is a prospective study that will recruit male and female study participants, ages 55 to 80, already enrolled in Lung Cancer Screening program at all Houston Methodist Hospital locations. The goal of this study is to develop powerful inte ... Read more >
